Ronit Mazor PhD

Dr. Ronit Mazor is a principal investigator and lab head in the FDA’s Gene Transfer Immunogenicity Branch in the Center for Biologics Evaluation and Research, where she leads a multi-disciplinary research team focused on evaluating and mitigating immunogenicity of gene therapy products. She serves as a primary reviewer of chemistry, manufacturing, and controls submissions for gene therapy products and BLA chair for first-in-class gene therapy products. Dr. Mazor's scientific contributions include high-impact publications, patents, and several FDA awards, including the Center Director Awards.

Her research encompasses T cell immunology, algorithm-based HLA binding predictions, investigation of sex-based immunological differences in gene therapy outcomes, and development of tolerogenic approaches to enhance therapeutic efficacy. Before joining the FDA, she conducted research at the National Cancer Institute, developing immune tolerance strategies for cancer immunotoxins, and served as a research lead at AstraZeneca, focusing on immunogenicity prediction for therapeutic proteins. Dr. Mazor holds a Ph.D. in Molecular Immunology from Tel Aviv University through the NIH Graduate Partnership Program and completed her postdoctoral training at the National Cancer Institute.